<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746313</url>
  </required_header>
  <id_info>
    <org_study_id>2020_18</org_study_id>
    <secondary_id>2020-A03066-33</secondary_id>
    <nct_id>NCT04746313</nct_id>
  </id_info>
  <brief_title>Prevalence of Hyperprolactinemia in Systemic Scleroderma</brief_title>
  <acronym>SCLERO-PRL</acronym>
  <official_title>Assessment of the Prevalence of Hyperprolactinemia in Systemic Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association pour la Formation et la Recherche en MÃ©decine Interne (AFORMI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by&#xD;
      fibrosis and vascular involvement. We know that the immune system is disrupted in systemic&#xD;
      sclerosis, but there are probably other mechanisms to explain the disease, including&#xD;
      deregulation of certain proteins such as prolactin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the prevalence of hyperprolactinemia in scleroderma patients</measure>
    <time_frame>At 2 years</time_frame>
    <description>Rate of prolactin measured by immuno-chemiluminescence (Abbott Architect automaton).&#xD;
The presence of a defined hyperprolactinemia at the University Hospital of Lille: for women, prolactin level higher than 26.5 ng/mL and for men, higher than 19.4 ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the prevalence of hyperprolactinemia between scleroderma patients and healthy subjects matched by age and sex</measure>
    <time_frame>At 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the associations between prolactin levels and clinical (scleroderma phenotype, visceral involvement) and biological (inflammation, antibodies, cytokines) manifestations in systemic sclerosis</measure>
    <time_frame>At 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between prolactin levels and biological markers of the immune system in scleroderma patients</measure>
    <time_frame>At 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sclerosis, Systemic</condition>
  <condition>Scleroderma</condition>
  <condition>Hyperprolactinemia</condition>
  <arm_group>
    <arm_group_label>Patients with systemic sclerosis</arm_group_label>
    <description>The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>to analysis prolactin in healthy subjects and scleroderma patients&#xD;
then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with systemic sclerosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Scleroderma patients are from scheduled hospitalization Department of Internal Medicine and&#xD;
        Clinical Immunology, CHU Lille Healthy subjects are from the French Blood Establishment&#xD;
        (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Scleroderma patients:&#xD;
&#xD;
          -  man or woman over 18 years old&#xD;
&#xD;
          -  with systemic sclerosis meeting ACR-EULAR 2013 criteria&#xD;
&#xD;
          -  having given his no opposition&#xD;
&#xD;
          -  being social insured&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  man or woman over 18 years old&#xD;
&#xD;
          -  donation of blood to the EFS&#xD;
&#xD;
          -  matched on age (+/- 5 years) and sex&#xD;
&#xD;
          -  having given his no opposition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Man or woman under 18 years old&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Receiving medical treatment inducing dysfunction of the hypothalamic pituitary axis&#xD;
&#xD;
          -  Refusing or unable to give no objection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Launay, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Launay, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>david.launay@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Claude Huriez Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>David Launay, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Prolactin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

